Filing Flows › Immucell (ICCC) › Q2 2025
Immucell (ICCC) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Immucell (ICCC) reported revenue of $6.4M for the second quarter 2025 (Q2 2025), +18% from a year earlier and -20% from the quarter before. Operating margin was 8.8%, net earnings $502K (7.8% of revenue).
Immucell, Q2 2025: revenue $6.4M (+18% year over year), operating margin 8.8%, net earnings $502K, operating cash flow $1.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.4M | -20% | +18% |
| Gross profit | $2.8M | -16% | +129% |
| Operating profit | $570K | -49% | — |
| Net earnings | $502K | -65% | — |
| Operating cash flow | $1.6M | +2% | +175% |
| Free cash flow | $1.4M | +16% | +207% |
What changed
Revenue was $6.4M in Q2 2025, up 18% year over year and down 20% from the previous quarter. First Defense Product Line was the largest line at 99% of revenue. First Defense Product Line added $1.0M year over year (up 18%), 100% of the total change.
Gross margin was 43.7%, up 21.2 points from a year earlier. Operating profit was $570K, a 8.8% margin (up 34.2 points year over year). Operating expenses fell 14% while revenue rose 18%. The fastest-growing cost line was General & admin (+20%). Net earnings were $502K. The effective tax rate was 0.4%.
Operating cash flow was $1.6M (up 175% year over year), 319% of net earnings. Non-cash charges added back $679K of depreciation and amortization and $67K of share-based compensation. Working capital and other items added $354K. Capital expenditures of $155K left free cash flow of $1.4M.
Questions
What was Immucell's revenue in the second quarter 2025?
Immucell (ICCC) reported revenue of $6.4M for the second quarter 2025 (Q2 2025), +18% from a year earlier and -20% from the quarter before.
Was Immucell profitable in the second quarter 2025?
Operating profit was $570K (8.8% of revenue) and net earnings $502K.
Source: Immucell 10-Q on SEC EDGAR.